Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 11,974 matching trials from the live ClinicalTrials.gov search.
Conditions
Non Small Cell Lung Cancer
Interventions
Nivolumab, Ramucirumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Conditions
Hepatoblastoma, Hepatocellular Carcinoma, Rhabdoid Tumor of Liver, Undifferentiated (Embryonal) Sarcoma of the Liver, Pediatric Liver Cancer, Liver Tumors
Interventions
Quality of Life Assessment, Transarterial Radioembolization
Behavioral · Radiation
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
0 Years to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Wilmington, Delaware • Jacksonville, Florida
Conditions
Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Non Small Cell Lung Cancer
Interventions
[18F]-αvβ6-BP
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Sacramento, California
Conditions
Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Histiocytosis, Hairy Cell Leukemia
Interventions
PLX8394
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington
Conditions
Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm, Fallopian Tube Serous Neoplasm, Ovarian Clear Cell Tumor, Ovarian Endometrioid Tumor, Ovarian Mucinous Tumor, Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Monitoring Device, Physical Activity, Quality-of-Life Assessment, Questionnaire Administration
Other · Device
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Interventions
Tiragolumab, Atezolizumab, Standard of Care, Questionnaires, Cisplatin, Carboplatin
Drug · Behavioral · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more
Conditions
Renal Cell Carcinoma
Interventions
TAK-228
Drug
Lead sponsor
Bradley A. McGregor, MD
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
La Jolla, California • Aurora, Colorado • Chicago, Illinois + 3 more
Conditions
Ovarian Carcinoma, Breast Carcinoma
Interventions
Computed Tomography, Copper Cu 64-DOTA B-Fab, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography
Diagnostic Test · Drug · Other
Lead sponsor
Sanjiv Sam Gambhir
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Bladder Carcinoma
Interventions
Intravesical BCG and EMDA/MMC
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Phoenix, Arizona • Aurora, Colorado
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Fluorine F 18 Sodium Fluoride
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts • Durham, North Carolina • Portland, Oregon + 1 more
Conditions
Hepatocellular Carcinoma
Interventions
Y90 + Atezolizumab and Bevacizumab, Y90 + TKI
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
7
States / cities
Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 4 more
Conditions
Colorectal Cancer Metastatic, Colon Cancer, Metastatic Colorectal Cancer, Rectal Cancer, Liver Metastasis Colon Cancer, Colo-rectal Cancer, Colorectal Adenocarcinoma, Colorectal Neoplasms, Liver Metastases, Colorectal Carcinoma
Interventions
Durvalumab, Yttrium-90 RadioEmbolization
Drug · Radiation
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Squamous Cell Carcinoma, Head And Neck
Interventions
WNT974
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Not applicable Interventional

Tka Assay for CDK4/6i

NCT06572800
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma
Interventions
DiviTum-TKa
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Derby, Connecticut • Fairfield, Connecticut • Glastonbury, Connecticut + 13 more
Conditions
Breast Carcinoma, Breast Ductal Carcinoma in Situ
Interventions
Patient Navigation, Questionnaire
Behavioral · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Non-small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Tucson, Arizona • Duarte, California • Glendale, California + 33 more
Conditions
Non-small Cell Lung Cancer
Interventions
gemcitabine, docetaxel, cisplatin, etoposide, radiation therapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
10
States / cities
Denver, Colorado • South Bend, Indiana • Baltimore, Maryland + 7 more
Conditions
Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology
Interventions
AGS-16C3F
Drug
Lead sponsor
Agensys, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
5
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Buffalo, New York + 2 more
Conditions
Non-Small-Cell Lung Carcinoma, Liver Cancer, Adrenal Cancer
Interventions
stereotactic body radiation therapy
Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Wilmington, North Carolina • Winston-Salem, North Carolina
Conditions
Atypical Choroid Plexus Papilloma, Choroid Plexus Carcinoma
Interventions
Melphalan, Carboplatin, Topotecan
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
0 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Clinical Observation, External Beam Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Standard Follow-Up Care, Therapeutic Conventional Surgery
Other · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Houston, Texas
Conditions
Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
trastuzumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Head and Neck Cancer
Interventions
Taxotere, Surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Boston, Massachusetts